Causal Evidence for Task Regulation by Anterior Cingulate Cortex
Launched by UNIVERSITY HOSPITAL, GHENT · Nov 24, 2020
Trial Information
Current as of August 19, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how damage to a specific part of the brain called the anterior cingulate cortex (ACC) affects a person's ability to manage tasks after experiencing a stroke. The ACC plays a role in selecting and motivating us to complete important tasks, and researchers want to understand how injuries to this area and other parts of the frontal lobe may impact daily functioning, as well as mood issues like depression and lack of motivation.
To participate in this study, individuals must be between 65 and 74 years old and have had a stroke that affected the frontal lobe, with visible damage shown on imaging tests like CT or MRI. Participants will need to be able to give consent for themselves and should not have certain conditions that could interfere with their ability to take part, such as severe dementia or active substance abuse. Those who join the study can expect to undergo assessments aimed at understanding their cognitive abilities and emotions following their stroke. This research could help improve our understanding of how brain injuries affect behavior and mood, leading to better treatments in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Stroke patients: ischemic stroke or intracranial hemorrhage
- • Involvement of the frontal lobe
- • Lesion is visible on CT and/or MRI and is concordant with clinical presentation during the time of onset
- • Patients have to be able to give informed consent themselves
- Exclusion Criteria:
- • Patients with a TIA, i.e. no visible lesion on CT and/or MRI or symptoms less than 24 hours
- • Patients with decreased alertness or disorders of consciousness, which makes it impossible for these patients to participate in the experiments
- • Active alcohol and/or drug abuse/addiction
- • Patients diagnosed with dementia or another neurodegenerative disease, or severe cognitive and/or psychiatric disorders that make it impossible for these patients to participate in the study
- • Patients with severe aphasia (as defined by NIHSS score)
- • A history of stroke in the frontal lobe is NOT an exclusion criteria (except when the patient has been diagnosed with poststroke frontal dysfunction).
About University Hospital, Ghent
University Hospital Ghent is a leading academic medical institution renowned for its commitment to advancing healthcare through innovative research and clinical trials. Located in Ghent, Belgium, the hospital is affiliated with Ghent University, fostering a collaborative environment that integrates cutting-edge medical research with high-quality patient care. With a diverse range of specialized departments and a dedicated team of researchers and clinicians, University Hospital Ghent is at the forefront of developing new therapies and improving treatment protocols, aiming to enhance patient outcomes and contribute to the global medical community.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Gent, , Belgium
Patients applied
Trial Officials
Veerle De Herdt
Principal Investigator
University Hospital Ghent, Department of Neurology
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials